AGIO Agios Pharmaceuticals, Inc.
USHealthcareAs of 2026-08-24
Why AGIO matters now
Agios Pharmaceuticals, Inc. (AGIO) is a US stock in Healthcare. The latest InvestLog snapshot shows $32.64 with -1.36% on the session and $1.95B in market capitalization; recent performance reads 1-month +23.19% and YTD +25.50%.
The latest financial table shown here is Q1 2026, with revenue of $20.7M, net income of $-99.1M, and EPS of $-1.69. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -18.9%.
The latest indexable market news headline is "Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $40.00; recent insider activity includes CAPELLO JEFFREY D filing M-Exempt; recent congressional disclosure data includes Gilbert Cisneros Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.81
P/S
30.76
EV/EBITDA
-4.67
DCF Value
$3.94
FCF Yield
-18.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
82.1%
Operating Margin
-720.0%
Net Margin
-639.8%
ROE
-34.1%
ROA
-35.7%
ROIC
-41.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $20.7M | $-99.1M | $-1.69 |
| Q4 2025 | $20.0M | $-108.0M | $-1.85 |
| FY 2025 | $54.0M | $-412.8M | $-7.12 |
| Q3 2025 | $12.9M | $-103.4M | $-1.78 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$43.33
Target (Median)
$40.00
Target Range
$36.00 - $54.00
Trading Activity
Insider Trades
Congress Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.59
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.